US FDA accepts regulatory submission for selumetinib in neurofibromatosis type 1 and grants Priority Review
14 November 2019 07:00 GMT US FDA accepts regulatory submission for selumetinibin neurofibromatosis type 1 and grants Priority Review AstraZeneca and MSD's selumetinib would become the first medicine indicated for the treatment of paediatric patients with NF1 plexiform neurofibromas if approved AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the US Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) and granted Priority Review for selumetinib as a potential new